Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of BRYHALI (IDP-122) lotion pharmacokinetics, absorption, safety and HPA axis in pediatric plaque psoriasis
2019-002209-23Phase 2Active
- Sponsor
- Bausch Health
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of minocycline in plaque psoriasis, sponsored by Bausch Health. Primary endpoints: Safety of IDP-122 (HP 0.01%) lotion and Systemic pharmacokinetics and absorption. Started Apr 2020; status: active.
02
Drugs
minocycline
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2019-002209-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002209-23.